Overview

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Collaborator:
Janssen R&D, L.L.C.
Treatments:
Rivaroxaban
Warfarin